

ABSTRACT SUBMISSION GUIDELINES

CATEGORIES

Pediatric asthma	Allergy diagnosis
Adult asthma	Biomarkers
Rhinitis	Biologics
Rhinosinusitis/Nasal polyps	Allergen immunotherapy
Atopic dermatitis	Allergy prevention/Risk factors
Urticaria/Angioedema	Microbiome
Other skin diseases	Immunodeficiency diseases
Anaphylaxis/mast cell related diseases	Immunomodulation and Nutrition
Food allergy	Basic allergy
Eosinophilic gastrointestinal disorders	Animal model
Drug allergy	Air pollution/Environmental
Ocular allergy	Occupational allergy
Insect venom	Miscellaneous

GUIDELINES FOR SUBMISSION

- The abstracts shall be submitted only via the online abstract system.
- Abstracts must be in English.
- Names of the authors should not include their academic titles.
- The names should be written with only the first letter in capital and the rest in small letters and without abbreviation.
- Name and country of the institution, in which the author is employed, should be stated.
- Only the first letter of the abstract title should be in capital letters (abbreviations will not be used).
- In case an abbreviation is used in the abstract, the abbreviation should be written open and the abbreviation in parenthesis.
- The purpose of the paper and the methods applied should be explained in brief, the findings should be summarized together with sufficient statistical details and the conclusion should be stated within the framework of the findings presented.
- Abstract should be organized in a way to include the titles of Background and objective, materials and methods, results and conclusions.



- The abstract length shall not exceed limits set in the online abstract system.
- Presenting author must register for the congress.
- Clinical trials and clinical studies should be registered in public clinical trial registries.
- Researcher must confirm they have obtained ethical approval from IRB board committee.

Please note:

- WAC2024 congress will not accept abstracts that have been accepted for publication at the time of submission.
- All abstracts accepted by WAC2024 are under the Embargo Policy.

ABSTRACT REVISION & ACCEPTANCE

Acknowledgement of the receipt of abstract submission will be sent to the Presenting author's email address upon submission. The Presenting Author will receive all correspondence regarding the abstract status, presentation type, date and time, via the email that is provided in the abstract submission.

The decision of Scientific Program Committee on abstract acceptance is final, while author's preferences for oral or poster presentations will be considered. The committee may offer an alternative format.

EMBARGO POLICY

All abstracts accepted to The World Allergy Congress (WAC 2024) are applied to embargo once the WAC 2024 Scientific Committee has notified presenters of their abstract's acceptance, and cannot be presented at other congress after this time. The following embargo policies are strictly enforced by the WAC 2024.

- Violation of this policy may result in the abstract being withdrawn from the congress and other measures deemed appropriate.
- Authors are responsible for informing co-authors, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy.

If you have questions about the WAC 2024 abstract embargo policy, please contact WAC 2024 abstracts team at info@worldallergy.org.

